Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,914,000 | 2,219,000 | 24,018,000 | 7,712,000 | 4,954,000 |
| Depreciation Amortization | 3,406,000 | 1,507,000 | N/A | N/A | 3,099,000 |
| Income taxes - deferred | 797,000 | 450,000 | N/A | N/A | 1,002,000 |
| Accounts receivable | -909,000 | -496,000 | -389,000 | N/A | N/A |
| Accounts payable and accrued liabilities | -132,000 | -143,000 | -21,000 | N/A | N/A |
| Other Working Capital | -2,065,000 | -2,644,000 | 241,000 | -2,394,000 | -2,488,000 |
| Other Operating Activity | 393,000 | 756,000 | -8,778,000 | 5,869,000 | -305,000 |
| Operating Cash Flow | $5,404,000 | $1,649,000 | $15,071,000 | $11,187,000 | $6,262,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -183,000 | 10,933,000 | -14,105,000 | 807,000 | 1,526,000 |
| PPE Investments | -468,000 | -224,000 | -1,138,000 | -752,000 | -482,000 |
| Net Acquisitions | -880,000 | -821,000 | 20,102,000 | -230,000 | -219,000 |
| Purchase Of Investment | -93,000 | -53,000 | -191,000 | -124,000 | -78,000 |
| Sale Of Investment | 96,000 | 66,000 | 442,000 | 408,000 | 428,000 |
| Purchase Sale Intangibles | -735,000 | -536,000 | -845,000 | -412,000 | -259,000 |
| Other Investing Activity | -735,000 | -536,000 | -902,000 | -464,000 | -298,000 |
| Investing Cash Flow | $-2,263,000 | $9,365,000 | $4,208,000 | $-355,000 | $877,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,955,000 | 478,000 | -3,524,000 | -1,174,000 | 8,000 |
| Debt Issued | 6,000 | 3,000 | 16,000 | N/A | N/A |
| Debt Repayment | -1,075,000 | N/A | -2,162,000 | -1,466,000 | -1,466,000 |
| Common Stock Issued | 100,000 | N/A | 53,000 | 53,000 | 53,000 |
| Common Stock Repurchased | -5,256,000 | -2,542,000 | -3,057,000 | -2,909,000 | -2,625,000 |
| Dividend Paid | -7,506,000 | -7,506,000 | -7,368,000 | -7,368,000 | -7,368,000 |
| Other Financing Activity | -54,000 | 39,000 | -222,000 | -149,000 | -81,000 |
| Financing Cash Flow | $-11,830,000 | $-9,528,000 | $-16,264,000 | $-13,013,000 | $-11,479,000 |
| Exchange Rate Effect | -93,000 | -41,000 | -266,000 | -266,000 | -201,000 |
| Beginning Cash Position | 12,407,000 | 12,407,000 | 9,658,000 | 9,658,000 | 9,658,000 |
| End Cash Position | 3,625,000 | 13,852,000 | 12,407,000 | 7,211,000 | 5,117,000 |
| Net Cash Flow | $-8,782,000 | $1,445,000 | $2,749,000 | $-2,447,000 | $-4,541,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,404,000 | 1,649,000 | 15,071,000 | 11,187,000 | 6,262,000 |
| Capital Expenditure | -514,000 | -257,000 | -1,378,000 | -918,000 | -567,000 |
| Free Cash Flow | 4,890,000 | 1,392,000 | 13,693,000 | 10,269,000 | 5,695,000 |